OBJECTIVE: To apply and analyze the mechanisms of action of dimethyldioctadecylammonium bromide (DDA), a powerful adjuvant that does not have the side effects of the conventionally used Freund's adjuvants, in proteoglycan-induced arthritis (PGIA) and collagen-induced arthritis (CIA). METHODS: PGIA and CIA were generated using standard immunization protocols with cartilage proteoglycan aggrecan (PG) or human type II collagen (CII) emulsified with Freund's complete adjuvant (CFA), and compared with PGIA and CIA generated using immunization protocols in which the same antigens were used in combination with the adjuvant DDA. Immune responses to immunizing and self PGs and CII, and the incidence, severity, and onset of arthritis were monitored throughout the experiments. In addition, a new, inexpensive, and powerful method of inducing arthritis using crude cartilage extracts is described. RESULTS: A significantly reduced onset period and a more severe arthritis were achieved in BALB/c mice immunized with cartilage PGs in DDA. PGs from bovine, ovine, and porcine cartilage, which otherwise have no effect or have only a subarthritogenic effect, and crude extracts of human osteoarthritic cartilage induced a 100% incidence with a very high arthritis score in BALB/c mice. The overall immune responses to either CII or PG were similar in antigen/CFA-immunized and antigen/DDA-immunized animals, but the Th1/Th2 balance shifted significantly toward a Th1 bias in DDA-injected animals with either PGIA or CIA. CONCLUSION: DDA, which was first used in autoimmune models, is a potent nonirritant adjuvant, which eliminates all undesired side effects of the Freund's adjuvants. DDA exerts a strong stimulatory effect via the activation of nonspecific (innate) immunity and forces the immune regulation toward Th1 dominance. These lines of evidence also suggest the possibility that seemingly innocuous compounds may exert an adjuvant effect in humans and may create the pathophysiologic basis of autoimmunity in susceptible individuals via the activation/stimulation of innate immunity.
OBJECTIVE: To apply and analyze the mechanisms of action of dimethyldioctadecylammonium bromide (DDA), a powerful adjuvant that does not have the side effects of the conventionally used Freund's adjuvants, in proteoglycan-induced arthritis (PGIA) and collagen-induced arthritis (CIA). METHODS: PGIA and CIA were generated using standard immunization protocols with cartilage proteoglycan aggrecan (PG) or human type II collagen (CII) emulsified with Freund's complete adjuvant (CFA), and compared with PGIA and CIA generated using immunization protocols in which the same antigens were used in combination with the adjuvant DDA. Immune responses to immunizing and self PGs and CII, and the incidence, severity, and onset of arthritis were monitored throughout the experiments. In addition, a new, inexpensive, and powerful method of inducing arthritis using crude cartilage extracts is described. RESULTS: A significantly reduced onset period and a more severe arthritis were achieved in BALB/c mice immunized with cartilage PGs in DDA. PGs from bovine, ovine, and porcine cartilage, which otherwise have no effect or have only a subarthritogenic effect, and crude extracts of humanosteoarthritic cartilage induced a 100% incidence with a very high arthritis score in BALB/c mice. The overall immune responses to either CII or PG were similar in antigen/CFA-immunized and antigen/DDA-immunized animals, but the Th1/Th2 balance shifted significantly toward a Th1 bias in DDA-injected animals with either PGIA or CIA. CONCLUSION:DDA, which was first used in autoimmune models, is a potent nonirritant adjuvant, which eliminates all undesired side effects of the Freund's adjuvants. DDA exerts a strong stimulatory effect via the activation of nonspecific (innate) immunity and forces the immune regulation toward Th1 dominance. These lines of evidence also suggest the possibility that seemingly innocuous compounds may exert an adjuvant effect in humans and may create the pathophysiologic basis of autoimmunity in susceptible individuals via the activation/stimulation of innate immunity.
Authors: Keith M Hamel; Yanxia Cao; Susan Ashaye; Yumei Wang; Robert Dunn; Marilyn R Kehry; Tibor T Glant; Alison Finnegan Journal: J Immunol Date: 2011-09-23 Impact factor: 5.422
Authors: Philip Stashenko; Reginaldo B Gonçalves; Brad Lipkin; Alexander Ficarelli; Hajime Sasaki; Antonio Campos-Neto Journal: Am J Pathol Date: 2007-01 Impact factor: 4.307
Authors: Adrienn Angyal; Colt Egelston; Tamás Kobezda; Katalin Olasz; Anna László; Tibor T Glant; Katalin Mikecz Journal: Arthritis Res Ther Date: 2010-03-18 Impact factor: 5.156
Authors: Jeroen N Stoop; Christopher A Tibbitt; Willem van Eden; John H Robinson; Catharien M U Hilkens Journal: Immunology Date: 2013-01 Impact factor: 7.397
Authors: Balint Farkas; Ferenc Boldizsar; Oktavia Tarjanyi; Anna Laszlo; Simon M Lin; Gabor Hutas; Beata Tryniszewska; Aaron Mangold; Gyorgy Nagyeri; Holly L Rosenzweig; Alison Finnegan; Katalin Mikecz; Tibor T Glant Journal: Arthritis Res Ther Date: 2009-02-16 Impact factor: 5.156
Authors: Lotte Wieten; Suzanne E Berlo; Corlinda B Ten Brink; Peter J van Kooten; Mahavir Singh; Ruurd van der Zee; Tibor T Glant; Femke Broere; Willem van Eden Journal: PLoS One Date: 2009-01-14 Impact factor: 3.240